Description of the SAGhE cohort: A large european study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone
- Swerdlow, A
- Cooke, R
- Albertsson Wikland, K
- Borgström, B
- Butler, G
- Clayton, P
- Coste, J
- Deodati, A
- Ecosse, E
- Gausche, R
- Giacomozzi, C
- Kiess, W
- Hokken Koelega, A
- Kuehni, C
- Landier, F
- Maes, M
- Mullis, P
- Pfaffle, R
- Sävendahl, L
- Sommer, G
- Thomas, M
- Tollerfield, S
- Zandwijken, G
- Carel, J.
- CIANFARANI, STEFANO
DOIAbstract
The long-term safety of growth hormone treatment is uncertain. Raised risks of death and certain cancers have been reported inconsistently, based on limited data or short-term follow-up by pharmaceutical companies
Add to ORKG